Grifols S.A. ADR Stock
Your prediction
Grifols S.A. ADR Stock
A loss of -2.110% shows a downward development for Grifols S.A. ADR.
Pros and Cons of Grifols S.A. ADR in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
C******** o* t** e**********
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Grifols S.A. ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Grifols S.A. ADR | -2.110% | 7.752% | 15.833% | -23.204% | -8.553% | -21.023% | -46.182% |
| Beximco Pharmaceuticals Ltd. GDR | -0.940% | 2.941% | 16.667% | 22.664% | 17.188% | 20.413% | -40.341% |
| Eledon Pharmaceuticals Inc. | -1.380% | -9.375% | -13.690% | 8.209% | 126.563% | 137.705% | -46.789% |
| SELLAS Life Sciences Group Inc | 12.210% | -12.851% | -25.812% | 502.778% | 206.173% | 479.439% | 20.556% |
Comments
Grifols, S.A. (NASDAQ: GRFS) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for GRFS provided by MarketBeat
Grifols, S.A. (NASDAQ: GRFS) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating.
Show more
Ratings data for GRFS provided by MarketBeat
Grifols, S.A. (NASDAQ: GRFS) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.
Show more
Ratings data for GRFS provided by MarketBeat
News
Grifols Q2 Earnings Call Highlights
Key Points
- Interested in Grifols, S.A.? Here are five stocks we like better.
- Grifols remains on track for its 2026 targets: First-half revenue rose 2.6% to €3.574 billion at constant currency
